NOVO.B.DK

370.4

+2.67%↑

COLO.B.DK

586.6

-1.77%↓

GMAB.DK

1,768

-0.39%↓

ZEAL.DK

432.5

+1.24%↑

AMBUB.DK

97.2

-1.02%↓

NOVO.B.DK

370.4

+2.67%↑

COLO.B.DK

586.6

-1.77%↓

GMAB.DK

1,768

-0.39%↓

ZEAL.DK

432.5

+1.24%↑

AMBUB.DK

97.2

-1.02%↓

NOVO.B.DK

370.4

+2.67%↑

COLO.B.DK

586.6

-1.77%↓

GMAB.DK

1,768

-0.39%↓

ZEAL.DK

432.5

+1.24%↑

AMBUB.DK

97.2

-1.02%↓

NOVO.B.DK

370.4

+2.67%↑

COLO.B.DK

586.6

-1.77%↓

GMAB.DK

1,768

-0.39%↓

ZEAL.DK

432.5

+1.24%↑

AMBUB.DK

97.2

-1.02%↓

NOVO.B.DK

370.4

+2.67%↑

COLO.B.DK

586.6

-1.77%↓

GMAB.DK

1,768

-0.39%↓

ZEAL.DK

432.5

+1.24%↑

AMBUB.DK

97.2

-1.02%↓

Search

H Lundbeck A-S

Затворен

43.66 1.11

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

43.18

Максимум

43.74

Ключови измерители

By Trading Economics

Приходи

-186M

966M

Продажби

-212M

6B

P/E

Средно за сектора

12.074

35.293

EPS

1.35

Дивидентна доходност

2.22

Марж на печалбата

16.039

Служители

5,700

EBITDA

811M

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.22%

3.07%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

6.9B

41B

Предишно отваряне

42.55

Предишно затваряне

43.66

H Lundbeck A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.09.2025 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17.09.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17.09.2025 г., 21:59 ч. UTC

Печалби

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17.09.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

17.09.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17.09.2025 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17.09.2025 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17.09.2025 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17.09.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17.09.2025 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17.09.2025 г., 21:00 ч. UTC

Печалби

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

17.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

17.09.2025 г., 19:59 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.09.2025 г., 19:59 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17.09.2025 г., 19:07 ч. UTC

Пазарно говорене

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17.09.2025 г., 18:43 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17.09.2025 г., 18:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17.09.2025 г., 18:20 ч. UTC

Пазарно говорене

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17.09.2025 г., 18:18 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.09.2025 г., 18:18 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17.09.2025 г., 18:14 ч. UTC

Пазарно говорене

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17.09.2025 г., 17:59 ч. UTC

Пазарно говорене

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17.09.2025 г., 17:15 ч. UTC

Придобивния, сливания и поглъщания

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17.09.2025 г., 17:06 ч. UTC

Придобивния, сливания и поглъщания

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17.09.2025 г., 16:51 ч. UTC

Печалби

Correct: Exor 1H Net Loss -EUR624M

17.09.2025 г., 16:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.09.2025 г., 16:34 ч. UTC

Пазарно говорене

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17.09.2025 г., 16:25 ч. UTC

Печалби

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17.09.2025 г., 16:23 ч. UTC

Печалби

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Сравнение с други в отрасъла

Ценова промяна

H Lundbeck A-S Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
help-icon Live chat